Aeglea Biotherapeutics, Inc. (AGLE)
| Market Cap | 78.76M |
| Revenue (ttm) | 5.81M |
| Net Income (ttm) | -85.44M |
| Shares Out | 94.20M |
| EPS (ttm) | -1.09 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 211,961 |
| Open | 1.16 |
| Previous Close | 1.21 |
| Day's Range | 1.16 - 1.31 |
| 52-Week Range | 0.37 - 6.86 |
| Beta | 1.91 |
| Analysts | Buy |
| Price Target | 3.83 (+208.9%) |
| Earnings Date | Nov 3, 2022 |
About AGLE
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, ... [Read more]
Financial Performance
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for AGLE stock is "Buy." The 12-month stock price forecast is 3.83, which is an increase of 208.87% from the latest price.
News
Aeglea BioTherapeutics Appoints Linda Neuman, M.D., M.B.A, to Chief Medical Officer
AUSTIN, Texas , Nov. 15, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative s...
Aeglea Biotherapeutics (AGLE) Reports Q3 Loss, Misses Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of 20.83% and 72.38%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics Reports Third Quarter 2022 Financial Results and Provides Program Updates
Interim Clinical Data from Phase 1/2 Trial of Pegtarviliase Expected in Fourth Quarter of 2022; Currently Dosing Cohort 3 at 1.35 mg/kg MAA for Pegzilarginase for the Treatment of Arginase 1 Deficiency ...
Aeglea BioTherapeutics Hosting Key Opinion Leader Webinar on Classical Homocystinuria and Pegtarviliase's Potential R...
Event to be Held Thursday, October 27 th at 10 AM ET AUSTIN, Texas , Oct. 19, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new ge...
Aeglea BioTherapeutics Provides Clinical Progress and Regulatory Update for Homocystinuria Program
AUSTIN, Texas , Oct. 4, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative sol...
Aeglea BioTherapeutics Announces Presentations at the Society for the Study of Inborn Errors of Metabolism (SSIEM) An...
AUSTIN, Texas , Aug. 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...
Paltalk And 3 Other Stocks Under $3 Insiders Are Aggressively Buying
The Dow Jones tumbled by over 500 points on Friday. Investors, meanwhile, focused on some notable insider trades.
Aeglea (AGLE) Down on Corporate Restructuring, CEO Steps Down
Aeglea (AGLE) announces a corporate restructuring plan to prioritize the development of AGLE-177 for patients living with homocystinuria. The company's current CEO resigns.
Aeglea BioTherapeutics Announces Leadership Transition and Corporate Restructuring
Prioritizing Resources and Focus on AGLE-177 and the Completion of the Ongoing Phase 1/2 Trial in Homocystinuria with Interim Clinical Data Expected in Q4 of 2022 Dr. Anthony Quinn, President, CEO and ...
Aeglea BioTherapeutics (AGLE) Seeks EU Nod for ARG1-D Treatment
Aeglea BioTherapeutics (AGLE) seeks a nod for its lead candidate, pegzilarginase, for treating ARG1-D in the European Union. Stock surges post announcement.
Aeglea BioTherapeutics Announces European Medicines Agency Validation of Marketing Authorization Application for Pegz...
AUSTIN, Texas , Aug. 18, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...
Aeglea Biotherapeutics (AGLE) Reports Q2 Loss, Lags Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of -3.85% and 55.99%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics Reports Second Quarter 2022 Financial Results and Provides Program Updates
Cohort 2 Completed in Phase 1/2 Trial of AGLE-177; Data Expected in Fourth Quarter of 2022 Actively Engaged with FDA to Identify Potential Paths Forward for Pegzilarginase Gross Proceeds of $45 Million ...
Aeglea (AGLE) Down on RTF Letter from FDA for Rare Disease Drug
Aeglea (AGLE) gets a Refusal to File letter from the FDA related to the biologics license application for pegzilarginase to treat arginase 1 deficiency. Stock down.
Aeglea BioTherapeutics Shares Plummet Following Refusal To File Letter From FDA
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) announced the U.S. Food and Drug Administration (FDA) has refused to accept the company's Biologics License Application (BLA) with a Refusal to File (RTF) let...
Aeglea BioTherapeutics Receives Refusal to File Letter from FDA for Pegzilarginase for the Treatment of Arginase 1 De...
AUSTIN, Texas , June 2, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...
Aeglea BioTherapeutics Announces $45 Million Registered Direct Offering Priced at a Premium to Market
AUSTIN, Texas , May 5, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as innovative solu...
Aeglea Biotherapeutics (AGLE) Reports Q1 Loss, Lags Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of -5.71% and 6.07%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Aeglea BioTherapeutics Reports First Quarter 2022 Financial Results and Provides Program Updates
Pegzilarginase BLA submitted to the FDA; if approved, pegzilarginase would be the first FDA-approved treatment for Arginase 1 Deficiency Additional PEACE data supporting potential efficacy of pegzilargi...
Aeglea (AGLE) Submits BLA for a Rare Disease Drug to the FDA
Aeglea (AGLE) files a biologics license application to the FDA for pegzilarginase to treat arginase 1 deficiency. The company has requested the FDA to grant priority review to the BLA.
Aeglea BioTherapeutics Submits BLA to FDA for Pegzilarginase for the Treatment of Arginase 1 Deficiency
BLA submission provides FDA with all pegzilarginase program data to review in detail; Aeglea looks forward to working collaboratively with the FDA on next steps in the review process If approved, pegzil...
Aeglea BioTherapeutics Presents Additional Data from PEACE Phase 3 Study of Pegzilarginase for the Treatment of Argin...
AUSTIN, Texas , April 11, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...
Aeglea BioTherapeutics to Participate in the Needham Virtual Healthcare Conferences in April 2022
AUSTIN, Texas , April 6, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peopl...
Aeglea BioTherapeutics Announces Presentation of Additional Data from PEACE Phase 3 Study of Pegzilarginase for the T...
AUSTIN, Texas , March 29, 2022 /PRNewswire/ -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics to benefit peop...
Aeglea Biotherapeutics (AGLE) Reports Q4 Loss, Tops Revenue Estimates
Aeglea (AGLE) delivered earnings and revenue surprises of 3.12% and 18.70%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?